A total of 132 patientswere screened for the study. Twenty-three
met inclusion criteria and provided written informed consent
with two withdrawing consent, resulting in 21 participants
available for analysis. The two patients that withdrew consent
did not attend scheduled appointments nor did they return phone
calls. Ten were randomized to group 1 and 11 randomized to
group 2. One participant in group 2 was unable to complete the
3-month evaluation secondary to cancer recurrence.